top of page
News & Events
The newspaper L'Arche showcased our work
Thanks to L'Arche for highlighting our work on RNA-targeted drug discovery for cancer
Congratulations to Liann for receiveing the Nanocenter Scholarship for outstanding PhD students.
New M.Sc. Students
We welcome to our lab two new Master students Esther and Leen! Good luck to them!
Excited to share our new publication in Advanced Science!
Our lab reports the first moleuclar degrader of a long noncoding RNA (lncRNA) — the telomeric transcript TERRA (Telomeric Repeat–Containing RNA). Congratulations to Elias Khaskia for his exceptional work leading this project and for pushing the boundaries of RNA-targeted chemistry!
Delighted to share our newest publication!
Marking the first PROTAC degrader for CB1R—in ACS Pharmacology & Translational Science! Huge congratulations to Aseel Kashkush for leading this groundbreaking study.
JACS AU cover
Thrilled to share that our work on druglike degraders of HuR has been selected for the JACS Au cover! Congrats to Liann & thanks to Ella Maru Studio for the stunning cover!
Best poster prize to Elias!
Congratulations to Elias for the best poster award at the 2025 MCS-ICS conference!
Congratulations to Aseel!
For receiving the Best Master's Student Prize from the Faculty of Medicine at the Hebrew University!
Extremely thrilled to share our latest article published in JACS Au!
"Druglike Molecular Degraders of the Oncogenic RNA-Binding Protein HuR"
In this study, we report the first-in-class small molecule degraders of HuR, designed using both molecular glue and PROTAC strategies.
💡 Our lead compounds:
-Induce a unique biphasic degradation of HuR via dual-pocket engagement
-Inhibit cancer progression in both 2D and 3D cancer cellular models
-Meet full drug-like criteria
This work demonstrates the power of targeted protein degradation to overcome the challenges of drugging structurally dynamic RBPs in cancer and RNA-driven diseases.
🎉 A special congratulations to Liann Kassabri, who initiated this project as an undergraduate student and led it to publication with outstanding dedication and scientific excellence.
In this study, we report the first-in-class small molecule degraders of HuR, designed using both molecular glue and PROTAC strategies.
💡 Our lead compounds:
-Induce a unique biphasic degradation of HuR via dual-pocket engagement
-Inhibit cancer progression in both 2D and 3D cancer cellular models
-Meet full drug-like criteria
This work demonstrates the power of targeted protein degradation to overcome the challenges of drugging structurally dynamic RBPs in cancer and RNA-driven diseases.
🎉 A special congratulations to Liann Kassabri, who initiated this project as an undergraduate student and led it to publication with outstanding dedication and scientific excellence.
bottom of page